North America Cancer Monoclonal Antibodies Market

North America Cancer Monoclonal Antibodies Market Size (2024 to 2029)

The size of the Cancer Monoclonal Antibodies Market in North America was worth USD 12.98 billion in 2024. This value is further expected to grow and worth USD 21.39  billion by the end of 2029, registering a CAGR of 10.5% from 2024 to 2029.

The market is mainly driven by the increasing number of patients suffering from different types of cancer. Growing demand to improve the quality of treatment procedures is surging the growth rate of the market. The rise in the revenue in both developed and developing countries are greatly influencing the demand for the cancer monoclonal antibodies market in North America. Growing support from the government and non-government organizations through investments in the construction o hospitals is propelling this market's demand. Also, increasing the scale of hospitals with the latest equipment is leveraging the growth of the market. 

Growing popularity in manufacturing new products with the latest technology is creating growth opportunities for the market. Increasing prevalence to promote the wellbeing of the patient after treatment is also likely to outshine the market demand. Escalating healthcare expenditure, especially in urban areas, is boosting up the growth rate of North American cancer monoclonal antibodies. 

However, lack of proper knowledge over the availability of different treatment procedures due to less training programs is slightly restricting the demand of the market. Fluctuations in the availability of raw materials are hindering the growth rate of this market in North America. Rapid changes in economic strategies are also impacting negatively on the growth of the cancer monoclonal antibodies market. Increasing prices of final products remain a challenging factor for the market. 

This research report on the North America Cancer Monoclonal Antibodies Market has been segmented and sub-segmented into the following categories:

By Application: 

• Liver
• Breast
• Blood
• Brain
• Hodgkin’s And Non-Hodgkin’s Lymphoma
• Colorectal
• Leukemia
• Others

By Type: 

• Murine Antibodies
• Chimeric & Humanised Antibodies
• Fully Humanized Antibodies

By Conjugated Cancer Therapies: 

• Immunoliposome
• Radioimmunotherapy
• ADEPT
• Immunocytokines
• Others

By Country: 

• The United States
• Canada
• Rest of North America

Regionally, North America is holding with the highest shares of the market, and the USA is the one ruling with dominant shares of the market in this region. Rising capital income is one of the most common factors propelling the growth of the market. Canada and Mexico are next to the USA in leading dominant shares of the market. Increasing investments in the development of new techniques in cancer treatment procedures elevates the growth rate of the cancer monoclonal antibodies market in North America. 

Promising companies operating in the North American Cancer Monoclonal Antibodies Market profiled in this report are Amgen, Genmab, Briston Myers Squibb, GlaxoSmithKline, Eli Lilly, Roche, Immunogen, Seattle Genetics, Novartis, and Spectrum Pharmaceuticals.